Articles tagged with Heart Failure
A meta-analysis of nearly 1,900 studies found that climbing stairs significantly reduces the risk of dying from cardiovascular disease. Regular stair climbing was associated with lower risks of heart-related problems and major cardiovascular conditions such as heart attack, stroke, and heart failure.
Dysregulated neutrophils may play a key role in persistent low-grade inflammation seen in chronic coronary syndrome. Researchers found that neutrophils from patients with stable coronary artery disease do not die as they should, persisting and remaining highly active.
The Marcus Foundation has awarded $28.7 million to advance a clinical trial testing a stem cell-based therapy designed to regenerate damaged heart tissue after a heart attack. Researchers aim to develop approaches that could reduce or eliminate the need for immunosuppressive drugs.
A new ACC Scientific Statement highlights the importance of considering cognitive impairment and frailty in cardiovascular care for older adults. The statement outlines practical strategies for prevention, screening, assessment, and management, aiming to improve outcomes such as independence, mobility, and caregiver burden.
A U-shaped association exists between LVEDD and mortality in HF, suggesting high risk for both abnormally small and large ventricles. The findings support integrating LV size assessment into routine risk stratification to guide personalized management.
Researchers created the most detailed map of gene regulation in human heart failure, revealing how genes are controlled in specific cell types. The study identified key shifts in cell composition, gene expression, and regulatory networks, pointing to new precision medicine therapies.
Heart failure affects over 60 million people worldwide and is a leading cause of hospitalization among older adults. The new expert statement highlights the importance of prevention and early intervention in reducing risk factors such as hypertension, diabetes, and obesity.
A study published in Nature Medicine found that a single daily dose of a polypill significantly enhances cardiac function and reduces hospitalizations for patients with heart failure. The treatment, which combines three types of medications, shows promise as a simplified approach to optimal therapy.
Researchers developed DeepHHF, an AI model that identifies patients at high risk of heart failure up to five years in advance. The model analyzes standard ECG recordings and detects subtle abnormalities that are often imperceptible to the human eye.
Researchers found minor cardiac dysfunction can predict microscopic tissue degradation in brain regions associated with Alzheimer's disease, leading to poor long-term memory performance.
Expanding heart failure care to pharmacists and nurse practitioner-led medication management can save approximately 10 lives and prevent 25 hospitalizations per 1,000 patients. This service is estimated to be cost-effective and improve patient outcomes, providing a roadmap for a stronger healthcare system.
The updated international definition of heart failure introduces a new classification system emphasizing earlier detection and personalized treatment. The revised framework standardizes terminology, recognizing that heart failure is not a static condition.
A new oral drug AC01 has been shown to improve heart function and be well-tolerated in patients with chronic heart failure. The study found no serious side effects and suggested potential clinical benefits, warranting further investigation.
Igor F. Palacios, MD, is honored for his groundbreaking work in structural heart disease interventions, including mitral balloon valvuloplasty and the percutaneous pericardial window technique. He has mentored hundreds of physician leaders worldwide through his kindness, generosity, and passion for patient-centered care.
A meta-analysis of studies found that guideline-recommended heart failure therapies protect heart function in patients treated for cancer. RAAS inhibitors and beta-blockers improved left ventricular ejection fraction, while mineralocorticoid antagonists showed encouraging protective effects.
The American Heart Association's Primary Care Perspectives platform provides practical education and tools to identify cardiovascular, kidney, and metabolic risk factors connected to heart failure. This initiative aims to improve long-term outcomes and reduce preventable disease progression by supporting earlier identification and mana...
A simple, seven-second X-ray scan can accurately detect the severity of pulmonary valve regurgitation in patients with repaired Tetralogy of Fallot. The test uses dynamic chest radiography and requires minimal radiation, offering a more accessible diagnostic option for those who cannot undergo traditional methods.
Adults with lower measured glomerular filtration rates had a higher risk of all-cause mortality, kidney failure, and major adverse cardiovascular events. Lower GFR values were also associated with increased hospitalization for heart failure and acute kidney injury.
Researchers at Max Delbrück Center uncover a previously unknown genetic mechanism regulating RBM20 protein in heart cells. The discovery reveals multiple transcription start sites for the gene and highlights the importance of isoform balance in disease progression.
The first national audit of advanced heart failure referrals reveals significant gaps in access to life-prolonging therapies, particularly for women. Women represent just 1 in 3 referrals, despite comparable disease burden.
New York Valves 2026 will unveil groundbreaking clinical science and innovation in transcatheter aortic valve replacement and mitral/tricuspid valve therapies. The conference features 22 late-breaking clinical science presentations that aim to transform the treatment of structural heart disease.
Researchers from The University of Osaka found that treatment with five mRNAs effectively promoted cardiac repair and extended survival in mice with heart failure. The study showed that simultaneous administration of five therapeutic mRNAs reduced heart tissue damage and improved heart function.
A new study by the University of Ottawa suggests that a tiny molecule, methylglyoxal, plays a major role in triggering neurological disorders after a heart attack. The molecule accumulates in the brain following a heart attack and is linked to depression, anxiety, and cognitive decline.
Researchers identified a key protein called PERM1 that is restored in patients whose hearts recover after left ventricular assist device (LVAD) support. PERM1 regulates energy production and contractile function in heart cells, and its normalization is associated with improved cardiac function.
A cohort study found two-thirds of newly diagnosed heart failure patients with reduced ejection fraction didn't undergo left ventricular ejection fraction reassessment, limiting treatment opportunities. Guideline-directed medical therapy was also underutilized among persistent heart failure patients who benefit most from it.
Patients with congenital heart defects are more likely to experience a first acute heart attack at an earlier age, averaging 58 years old. Despite this, there is no difference in mortality rates or risk of further heart attacks between the group with congenital heart defects and those without.
A major international study has identified ways to detect patients with hypertrophic cardiomyopathy at serious risk of sudden death, heart failure or other dangerous outcomes. The findings will help save lives by improving the ability to determine who is at greatest risk and spare low-risk patients from unneeded heart implants.
Researchers found a high-risk subgroup of patients with the 'lemon-on-sticks' phenotype, characterized by low BMI and high WHR, who had poor outcomes and higher all-cause mortality rates compared to other phenotypes. This study highlights the need for personalized therapy in heart failure.
In patients with symptomatic rheumatic heart disease, digoxin significantly reduced the risk of a composite of all-cause death or new-onset or worsening heart failure. The treatment had little risk of toxicity, making it a promising therapeutic option for these patients.
The HF-REVERT trial found that CDR132L improved secondary endpoints, including LVEF and NT-proBNP, but not the primary endpoint of LVESVI. Target engagement was confirmed by decreased plasma levels of microRNA-132. The therapy was well-tolerated with no significant safety concerns.
Treatment with digitalis glycosides reduces worsening heart failure events in HFmrEF and HFrEF patients, suggesting its use as additional therapy to reduce worsening heart failure events. The study found no significant interaction with other important study characteristics.
Researchers found that low-dose digoxin and digitoxin reduced worsening heart failure events in patients with mild-to-moderate heart failure and reduced ejection fraction. The treatment was generally well-tolerated and safe, offering a cheap and effective option for managing the condition.
A global validation study led by NYU Langone Health confirms the accuracy of the American Heart Association's PREVENT tool in predicting cardiovascular disease (CVD) risk for diverse populations. The tool, which considers kidney health and albuminuria levels, was found to be highly effective in identifying patients at high CVD risk.
Dr. Rebecca T. Hahn, MD, is the first imager to receive the TCT Geoffrey O. Hartzler Master Operator Award for her groundbreaking work in imaging structural heart procedures. Her unparalleled expertise has redefined the role of imaging in cardiovascular care.
Patrick T. O'Gara, a master clinician and educator, will receive the TCT 2026 Career Achievement Award for his groundbreaking work in interventional cardiology. The award recognizes his clinical excellence, pioneering research, and mentorship of the next generation of physicians.
High-intensity interval training shows strongest vascular benefits in cardiovascular patients. HIIE consistently improves flow-mediated dilation and vasodilation, with combined high-intensity programs showing the largest estimated effects on endothelial function.
Advances in pediatric heart care have increased survival rates, but a shortage of donor hearts means many children still die waiting. Experts urge a shift from 'perfect' donor hearts to carefully selected organs and technological innovations to expand the donor pool.
Researchers are using space-based experiments to develop new methods for protecting and repairing heart tissue, with the goal of creating more robust tissue engineering techniques. By studying the effects of microgravity on heart tissue, scientists hope to identify new targets for therapy and improve patient outcomes.
Experts at ISHLT's annual meeting explored how countries allocate heart transplants, with a focus on balancing competing priorities like saving the sickest patients and ensuring fairness. The discussion highlighted key differences in global allocation schemes, including France's data-driven model, which aims to prioritize patients base...
Partial heart transplantation replaces only defective valves and related structures, eliminating need for repeat replacements. This procedure can provide thousands of additional valve transplants annually, benefiting young patients worldwide.
Researchers found that people with severe obesity and heart failure have weakened heart muscles, which can be reversed through weight loss. The study identified a chemical change in a protein called troponin I as the underlying cause of this condition.
A new global allocation system is being proposed to address inequities in organ allocation for heart transplants. The proposal aims to reduce disparities and ensure no viable donor heart goes unused globally.
A new multicenter study finds that reoperative surgical mitral valve replacement demonstrates significant long-term survival benefits over transcatheter mitral valve-in-valve procedures in patients with failing bioprosthetic valves. At five years, rSMVR patients had lower mortality and more favorable valve performance.
A recent review highlights how AI enables precision treatment, continuous monitoring and individualized prognostic modeling for heart failure patients. AI integrates large-scale structured electronic health records and multimodal imaging to characterize cardiac structure and function, enhancing diagnostic accuracy.
A randomized trial demonstrated that Left Bundle Branch Area Pacing (LBBAP) is an effective strategy for cardiac resynchronisation in patients with heart failure. LBBAP was found to reduce device-related complications and procedure times compared to biventricular pacing.
Individuals with screening-detected atrial fibrillation have a threefold increased risk of developing heart failure compared to those without AF. The incidence of HF was diagnosed early after AF detection, emphasizing the importance of identifying and treating HF in patients with AF.
Combining resistance training and aerobic exercises significantly enhances aerobic fitness, muscle strength, and walking distance in heart failure patients. Adding resistance training to aerobic workouts increases muscle strength more than exercising aerobically alone.
A new study found that older people who forego necessary dental procedures due to financial barriers may experience heart failure, a heart attack, a stroke, or dementia. The researchers suggest that alleviating upstream factors such as financial constraints could prevent chronic disease.
A post hoc analysis of the Finerenone Trial reveals that sudden death in heart failure was often preceded by modest worsening of symptoms and declining quality of life. The study suggests limited specificity for sudden death among other modes of death, implying a complex trajectory before modes of death.
The EMPEROR-Preserved risk model demonstrated good performance in the FINEARTS-HF trial, showing that baseline risk does not modify the relative treatment effect of finerenone. Finerenone has been shown to have a significant benefit for heart failure patients.
A new study finds that heart failure and atrial fibrillation share similar genetic and molecular mechanisms, suggesting a more nuanced understanding of these two conditions. The research reveals that the pathological response involves multiple cell types communicating with each other, leading to a fundamental shift in how atrial fibril...
A study of over 25,300 participants found that consuming a high amount of dietary salt (4,200mg/day) increases the risk of new-onset heart failure by 15%. Reducing sodium intake could lead to a significant reduction in heart failure cases and deaths.
Registration is now open for TCT 2026, the annual scientific symposium of CRF, taking place October 31 - November 3 in San Diego. The event will feature a dynamic program with groundbreaking research and expert-led tutorials.
A new 4D digital heart model has been shown to improve patient outcomes in cardiac resynchronization therapy (CRT) for heart failure. The model, developed at the University of Calgary, enables personalized pacemaker placement, leading to a 10.8% increase in heart function compared to standard care.
A new AI-powered method predicts peak oxygen consumption with high accuracy, identifying high-risk patients with advanced heart failure. The study's multi-modal model uses cardiac ultrasound images and electronic health records to detect this critical measure.
A new study reveals that prior authorization requirements for heart failure medications can significantly delay pharmacy fills, particularly for those with lower socioeconomic status or Medicaid insurance. The study found that patients with prior authorization prescriptions took three times as long to fill their ARNI prescriptions and ...
Researchers at Rice University developed a CRISPR-based technique that increases mitochondrial production in heart cells, improving energy levels and pumping contractions. The system successfully boosted mitochondrial function in human cell types, animal models, and adult human heart donor tissue.
A new study by Cleveland Clinic and Dyania Health demonstrates the potential of large language models in accurately identifying patients who could benefit from clinical research. The AI system reviewed 1,476 patients and identified 46 as potential matches, resulting in a more diverse patient population.
A study published in European Heart Journal found that nearly half of hospitalised heart failure patients are readmitted within a year, with the risk of death also remaining high. Patients with severely reduced heart function face the highest risk, highlighting the need for careful follow-up and tailored care.
Researchers found that a bacterial metabolite regulates heart function through specific brain cells, revealing a new gut-brain-heart axis. This discovery points to potential therapies for hypertension and heart failure, and may serve as a biomarker for identifying patients at high risk.